This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Mcgill University, National Institute of Health and Medical Research, Université D'angers. Active years: 2016.
Company Filing History:
1 out of 570 
1 out of 1,853 
1 out of 55 
Years Active: 2016
Title: The Innovative Contributions of Julien Balzeau
Introduction
Julien Balzeau is a notable inventor based in Segre, France. He has made significant strides in the field of medical research, particularly in the treatment of malignant glioma, a prevalent type of primary tumor of the central nervous system. His work has the potential to impact the lives of many patients suffering from this aggressive form of cancer.
Latest Patents
Julien Balzeau holds a patent for the use of a neurofilament peptide for the treatment of glioma. The invention provides a new drug that specifically targets glioma cells, triggering apoptosis and offering a promising method for treating this challenging condition. The isolated NFL-TBS peptide is highlighted for its specificity in detecting glioma cells, whether in vivo or in vitro, and for its potential in delivering chemical compounds directly to tumor cells.
Career Highlights
Throughout his career, Balzeau has been associated with prestigious institutions such as the University of Angers and the National Institute of Health and Medical Research. His research has focused on innovative approaches to cancer treatment, showcasing his commitment to advancing medical science.
Collaborations
Julien Balzeau has collaborated with esteemed colleagues, including Alan Peterson and Joël Eyer. These partnerships have contributed to the development and refinement of his groundbreaking research.
Conclusion
Julien Balzeau's contributions to the field of glioma treatment exemplify the impact of innovative research in medicine. His patent and collaborative efforts highlight the importance of targeted therapies in improving patient outcomes.